Summary
In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major subject areas are agreed in order to ensure that the conduct of the clinical trial does not cause issues when the new drug application is assessed by the competent authorities. Although Local Representation applies to multiple areas of Pharmaceutical Development (Regulatory, Legal, etc.), this Whitepaper is limited to the area of Pharmacovigilance.
Register to download
Local Representation: What Clinical Trial Sponsors Need to Know
You may also be interested in:
page
Medical Science Liaisons
PRA’s Medical Science Liaisons (MSLs) are highly skilled and trained scientific resources working for you throughout every step of product…
Newsletter
Pharmacovigilance Nugget #2 Generating a DSUR - November 2017
A Development Safety Update Report (DSUR) is a periodic regulatory safety report used for drugs under development and for marketed products that are…
Newsletter
Pharmacovigilance Nugget #1 Adjudication - August 2017
Data that has a level of confidence, validity, and reliability is crucial to the success of a clinical trial and to bringing the investigational…